These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 9669419)

  • 41. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Are antihypertensive drugs similar in protecting the kidney?
    Ritz E
    Am J Hypertens; 1995 Oct; 8(10 Pt 2):53S-58S. PubMed ID: 8845084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduced dietary salt for prevention of cardiovascular disease.
    Hooper L; Bartlett C; Davey SM; Ebrahim S
    Cochrane Database Syst Rev; 2003; (1):CD003656. PubMed ID: 12535482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of sodium restriction and diuretic therapy for "resistant" hypertension in chronic kidney disease.
    Sinnakirouchenan R; Kotchen TA
    Semin Nephrol; 2014; 34(5):514-9. PubMed ID: 25416660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salt and blood pressure responses to calcium antagonism in hypertensive patients.
    Weir MR; Hall PS; Behrens MT; Flack JM
    Hypertension; 1997 Sep; 30(3 Pt 1):422-7. PubMed ID: 9314427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salt and hypertension: is salt dietary reduction worth the effort?
    Frisoli TM; Schmieder RE; Grodzicki T; Messerli FH
    Am J Med; 2012 May; 125(5):433-9. PubMed ID: 22482843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advice to reduce dietary salt for prevention of cardiovascular disease.
    Hooper L; Bartlett C; Davey SG; Ebrahim S
    Cochrane Database Syst Rev; 2004; (1):CD003656. PubMed ID: 14974027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
    Ruggenenti P; Perna A; Mosconi L; Pisoni R; Remuzzi G
    Kidney Int; 1998 May; 53(5):1209-16. PubMed ID: 9573535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
    Khan NA; Hemmelgarn B; Padwal R; Larochelle P; Mahon JL; Lewanczuk RZ; McAlister FA; Rabkin SW; Hill MD; Feldman RD; Schiffrin EL; Campbell NR; Logan AG; Arnold M; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Leiter LA; Ogilvie RI; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Burns KD; Ruzicka M; deChamplain J; Pylypchuk G; Gledhill N; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Touyz RM; Tobe SW;
    Can J Cardiol; 2007 May; 23(7):539-50. PubMed ID: 17534460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A practical approach to achieving recommended blood pressure goals in diabetic patients.
    Bakris GL
    Arch Intern Med; 2001 Dec 10-24; 161(22):2661-7. PubMed ID: 11732930
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency?
    Weir MR
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):195S-203S. PubMed ID: 10619572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal effects of antihypertensive drugs.
    Schlueter WA; Batlle DC
    Drugs; 1989 Jun; 37(6):900-25. PubMed ID: 2667938
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans.
    Kaperonis N; Bakris G
    Curr Opin Nephrol Hypertens; 2003 Jan; 12(1):79-84. PubMed ID: 12496670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.